Progression of Renal Dysfunction in Patients with Cardiovascular Disease

It has been established that patients with chronic kidney disease (CKD) suffer from frequent cardiovascular events. On the other hand, recent studies suggest that renal damage tends to worsen in patients with cardiovascular diseases (CVD). Although the mechanisms for the cardiorenal association are unclear, the presence of arteriosclerotic risk factors common to both CVD and CKD is important. In arteriosclerosis, vascular derangement progresses not only in the heart but also in the kidney. In addition, heart failure, cardiac catheterization and hesitation of medical treatments due to renal dysfunction may explain the progression of renal damage. Therefore, the goal of treatments is a total control of arteriosclerotic risk factors. Medication should be selected among agents with protective effects on both heart and kidney. It is important to always consider the presence of CKD for the treatment of the cardiovascular disease and strictly control the risk factors.

[1]  Charles E McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[2]  L. Smeeth,et al.  Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis , 2005, The Lancet.

[3]  G. Burke,et al.  Tobacco, hypertension, and vascular disease: risk factors for renal functional decline in an older population. , 2000, Kidney international.

[4]  Robert M Califf,et al.  Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. , 2004, The New England journal of medicine.

[5]  Hans L. Hillege,et al.  Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure , 2006, Circulation.

[6]  A. Colombo,et al.  Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): A Randomized Comparison of 3 Preventive Strategies , 2007, Circulation.

[7]  T. Imaizumi,et al.  Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. , 1998, Life sciences.

[8]  P. Whelton,et al.  End-stage renal disease in African-American and white men. 16-year MRFIT findings. , 1997, JAMA.

[9]  R. Bigazzi,et al.  Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. , 2006, Kidney international.

[10]  J. Strong,et al.  Renovasculopathies of nephrosclerosis in relation to atherosclerosis at ages 25 to 54 years. , 1996, Kidney international.

[11]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[12]  R. Schrier.  Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor? , 2006, Journal of the American College of Cardiology.

[13]  A. Sugawara,et al.  Nongenomic vascular action of aldosterone in the glomerular microcirculation. , 2003, Journal of the American Society of Nephrology : JASN.

[14]  B. Davis,et al.  Cardiovascular Outcomes in High-Risk Hypertensive Patients Stratified by Baseline Glomerular Filtration Rate , 2006, Annals of Internal Medicine.

[15]  P. Bacchetti,et al.  Low ankle-brachial index associated with rise in creatinine level over time: results from the atherosclerosis risk in communities study. , 2005, Archives of internal medicine.

[16]  F. Veglia,et al.  N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. , 2006, The New England journal of medicine.

[17]  T. Tagami,et al.  Molecular Mechanism of the Inhibitory Effect of Aldosterone on Endothelial NO Synthase Activity , 2006, Hypertension.

[18]  J Singer,et al.  Cardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[19]  G. Chertow,et al.  Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. , 2005, Journal of the American Society of Nephrology : JASN.

[20]  E. Tuzcu,et al.  Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. , 2006, Journal of the American College of Cardiology.

[21]  K. Iseki,et al.  Blood Pressure Predicts Risk of Developing End‐Stage Renal Disease in Men and Women , 2003, Hypertension.

[22]  R. Nagai,et al.  A case of cholesterol embolism confirmed by skin biopsy and successfully treated with statins and steroids. , 2006, The American journal of the medical sciences.

[23]  B. Kasiske.  Relationship between vascular disease and age-associated changes in the human kidney. , 1987, Kidney international.

[24]  Daniel Levy,et al.  Predictors of new-onset kidney disease in a community-based population. , 2004, JAMA.

[25]  Keith C. Norris,et al.  Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). , 2007, Archives of internal medicine.

[26]  G. Bakris,et al.  Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[27]  J. Moorhead.  Lipids and progressive kidney disease. , 1991, Kidney international. Supplement.

[28]  J. D'Elia,et al.  Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. , 1994, The New England journal of medicine.

[29]  J. Griffith,et al.  Cardiovascular disease and subsequent kidney disease. , 2007, Archives of internal medicine.